Hansoh Pharmaceutical Group reported first-half 2026 revenue of approximately 8.3 billion yuan ($1.2 billion), up 11.7% from a year earlier, while profit rose 35.8% to about 4.26 billion yuan ($634.5 million). Innovative-drug revenue increased 21.6% to approximately 7.09 billion yuan, accounting for a record 85.4% of sales, with oncology products contributing 5.47 billion yuan. The company is expanding its pipeline and overseas licensing activity, including a potential $2.3 billion deal for HS-20118 with Avere Therapeutics, while advancing the B7-H3 ADC HS-20093 and the GLP-1/GIP weight-management candidate oleperptide. Hansoh spent 1.74 billion yuan on research and development in the first half and held 37.38 billion yuan in cash and bank balances at June 30. The company previously reported that other income more than doubled to 1.32 billion yuan and declared an interim dividend of HK$0.285 per share, compared with HK$0.2316 a year earlier.